Cellectis (ALCLS) - Cash Flow Conversion Efficiency

Latest as of June 2026: -0.348x

Based on the latest financial reports, Cellectis (ALCLS) has a cash flow conversion efficiency ratio of -0.348x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-14.28 Million ≈ $-16.70 Million USD) by net assets (€41.07 Million ≈ $48.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Cellectis for the company's overall valuation and market capitalisation.

Cellectis - Cash Flow Conversion Efficiency Trend (2005–2025)

This chart illustrates how Cellectis's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Cellectis Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cellectis ranked by their cash flow conversion efficiency. Explore ALCLS cash flow quality index to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
MDxHealth SA ADR NASDAQ:MDXH	0.192x
Paramount Gold Nevada Corp NYSE MKT:PZG	0.070x
Jindal Poly Investment and Finance Company Limited NSE:JPOLYINVST	0.004x
Kino Indonesia Tbk PT JK:KINO	0.132x
Reward Wool Industry Corp TW:1423	0.004x
Jiin Ming Industry Co Ltd TWO:3230	0.026x
Orion Energy Systems Inc NASDAQ:OESX	0.072x
New Horizon Aircraft Ltd NASDAQ:HOVR	-0.066x

Annual Cash Flow Conversion Efficiency for Cellectis (2005–2025)

The table below shows the annual cash flow conversion efficiency of Cellectis from 2005 to 2025. View ALCLS stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€75.87 Million ≈ $88.70 Million	€-41.64 Million ≈ $-48.69 Million	-0.549x	-412.85%
2024-12-31	€131.03 Million ≈ $153.19 Million	€22.99 Million ≈ $26.88 Million	0.175x	+160.05%
2023-12-31	€84.69 Million ≈ $99.02 Million	€-24.75 Million ≈ $-28.93 Million	-0.292x	+57.92%
2022-12-31	€125.94 Million ≈ $147.24 Million	€-87.44 Million ≈ $-102.23 Million	-0.694x	-57.03%
2021-12-31	€236.47 Million ≈ $276.46 Million	€-104.56 Million ≈ $-122.24 Million	-0.442x	-70.15%
2020-12-31	€308.85 Million ≈ $361.07 Million	€-80.26 Million ≈ $-93.83 Million	-0.260x	-33.61%
2019-12-31	€355.47 Million ≈ $415.58 Million	€-69.14 Million ≈ $-80.83 Million	-0.195x	-28.54%
2018-12-31	€450.27 Million ≈ $526.41 Million	€-68.14 Million ≈ $-79.66 Million	-0.151x	+17.32%
2017-12-31	€285.90 Million ≈ $334.25 Million	€-52.33 Million ≈ $-61.18 Million	-0.183x	-61.34%
2016-12-31	€274.05 Million ≈ $320.39 Million	€-31.09 Million ≈ $-36.34 Million	-0.113x	-1024.12%
2015-12-31	€288.22 Million ≈ $336.95 Million	€3.54 Million ≈ $4.14 Million	0.012x	-98.25%
2014-12-31	€72.39 Million ≈ $84.63 Million	€50.74 Million ≈ $59.32 Million	0.701x	+118.19%
2013-12-31	€6.65 Million ≈ $7.77 Million	€-25.63 Million ≈ $-29.96 Million	-3.854x	-1105.67%
2012-12-31	€81.69 Million ≈ $95.50 Million	€-26.11 Million ≈ $-30.53 Million	-0.320x	+10.29%
2011-12-31	€37.02 Million ≈ $43.28 Million	€-13.19 Million ≈ $-15.42 Million	-0.356x	+15.35%
2010-12-31	€50.13 Million ≈ $58.60 Million	€-21.10 Million ≈ $-24.67 Million	-0.421x	-337.25%
2009-12-31	€73.22 Million ≈ $85.60 Million	€-7.05 Million ≈ $-8.24 Million	-0.096x	-350.06%
2008-12-31	€46.21 Million ≈ $54.03 Million	€1.78 Million ≈ $2.08 Million	0.038x	+129.82%
2007-12-31	€43.54 Million ≈ $50.91 Million	€-5.62 Million ≈ $-6.57 Million	-0.129x	-400.76%
2005-12-31	€9.11 Million ≈ $10.65 Million	€391.00K ≈ $457.12K	0.043x	--

About Cellectis

PA:ALCLS France Biotechnology

Market Cap

$111.46 Million

€95.33 Million EUR

Market Cap Rank

#18897 Global

#273 in France

Share Price

€1.31

Change (1 day)

+7.28%

52-Week Range

€1.15 - €4.57

All Time High

€40.90